Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

  • Articles  (3)
  • Blackwell Science Pty  (1)
  • German Medical Science; Düsseldorf, Köln  (1)
  • The American Association for Clinical Chemistry (AACC)  (1)
  • 1
    German Medical Science; Düsseldorf, Köln
    In:  51. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie; 20060910-20060914; Leipzig; DOC06gmds056 /20060901/
    Publication Date: 2006-09-25
    Keywords: ddc: 610
    Language: German
    Type: conferenceObject
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1440-1681
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: 1. The purpose of the present study was to test the effects of synthetic atrial natriuretic peptide (ANP) on renal haemodynamics and excretory capacities of salt and water in the rat during an ‘acute volumic stress’, which was induced by brisk disturbances of the circulatory volume.2. To this end, 29 anaesthetized male Wistar rats were rapidly injected with 1 mL of 0.85% NaCl, repeated twice at 60 s intervals. The injectates contained no ANP (n = 5) or 1 × 0.25 (n = 6), 3 × 0.25 (n = 6), 1 × 2.5 (n = 6) or 3 × 2.5 μg (n = 6) ANP, added to the first injectate only (1 ×) or to each injectate (3 ×). Renal blood flow (RBF) was continuously measured with an electromagnetic flow transducer.3. Renal blood flow increased transiently (approximately 30 s) by approximately 13% (P 〈 0.05) during each injection of saline without ANP. Addition of 0.25 or 2.5 μg ANP to the first injectate enhanced RBF by 21 and 35%, respectively (both P 〈 0.05), but did not modify the time sequence. Furthermore, addition of 0.25 μg ANP to the second and third injectate produced an almost similar change in RBF at the end of each injection (ΔRBF = 20 and 17%, respectively). In contrast, the addition of 2.5 μg ANP to the second and third injectate did not produce the same changes in RBF observed at the end of the first injection. The amplitude of the change in RBF was then similar to the increase in RBF induced by 1 mL saline without ANP. Mean arterial pressure (MAP) did not change significantly during repeated injections of saline alone or with addition of 0.25 μg ANP to the first injectate. However, MAP decreased significantly (by 5, 9 and 9 mmHg) after the injection of 3 × 0.25, 1 × 2.5 or 3 × 2.5 μg ANP, respectively.4. Sodium excretion was rapidly increased from 2.600±0.654 to 9.330±1.322 μmol/min after injection of 3 × 1 mL of 0.85% NaCl (P 〈 0.05). Thereafter, sodium excretion remained enhanced throughout the experiment, so that 70% of the sodium load injected was recovered at the end of the experiment. Atrial natriuretic peptide added to the injectates further elevated the maximal responses in diuresis and natriuresis induced by saline injections without ANP (P 〈 0.001). A maximal effect was observed after the addition of 2.5 μg ANP to the first saline solution. When the amount of sodium excreted was calculated by integrating the areas under the curve of the natriuretic responses, a relationship was established as a function of the amount of ANP added to the saline solutions. It was characterized by a threshold in the presence of 2.5 μg ANP added to the first injectate when the integration period was limited to 4 min 30 s and 14 min 30 s after starting the first injection of the varying test solutions. When the integration period was extended until the end of the experiment (2 h), the amount of sodium excreted in each group was further enhanced, especially after injection of 3 × 1 mL of 0.85% NaCl without ANP or with 1 × 0.25 and 3 × 0.25 μg ANP. Differences in sodium excretion between groups were attenuated (P 〈 0.054, ANOVA).5. In conclusion, our results demonstrate differential effects of synthetic ANP on renal vascular reactivity and excretory capacity. These effects were superimposed on changes induced by acute volumic stress. In particular, effects of saline injections on renal vascular compliance were amplified in the presence of ANP added in varying amounts to the injectates. This amplification was limited to 2.5 μg ANP.
    Type of Medium: Electronic Resource
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    Publication Date: 2018-01-30
    Description: BACKGROUND: Progress in the liquid biopsy field, combined with the development of droplet digital PCR (ddPCR), has enabled noninvasive monitoring of mutations with high detection accuracy. However, current assays detect a restricted number of mutations per reaction. ddPCR is a recognized method for detecting alterations previously characterized in tumor tissues, but its use as a discovery tool when the mutation is unknown a priori remains limited. METHODS: We established 2 ddPCR assays detecting all genomic alterations within KRAS exon 2 and EGFR exon 19 mutation hotspots, which are of clinical importance in colorectal and lung cancer, with use of a unique pair of TaqMan ® oligoprobes. The KRAS assay scanned for the 7 most common mutations in codons 12/13 but also all other mutations found in that region. The EGFR assay screened for all in-frame deletions of exon 19, which are frequent EGFR-activating events. RESULTS: The KRAS and EGFR assays were highly specific and both reached a limit of detection of 〈0.1% in mutant allele frequency. We further validated their performance on multiple plasma and formalin-fixed and paraffin-embedded tumor samples harboring a panel of different KRAS or EGFR mutations. CONCLUSIONS: This method presents the advantage of detecting a higher number of mutations with single-reaction ddPCRs while consuming a minimum of patient sample. This is particularly useful in the context of liquid biopsy because the amount of circulating tumor DNA is often low. This method should be useful as a discovery tool when the tumor tissue is unavailable or to monitor disease during therapy.
    Keywords: Cancer Diagnostics (since 2002)
    Print ISSN: 0009-9147
    Electronic ISSN: 1530-8561
    Topics: Medicine
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...